Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Based on their findings, the researchers suggest a potential need for screening for coexisting sleep disorder symptoms in patients with respiratory symptoms.

Researchers Find Higher Risk of Insomnia With Undiagnosed Asthma

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton tyrosine kinase inhibitor treatment 6 months after the fixed-duration period.

Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World 

The health policy implications and ballot measures in the wake of the presidential election, new trends in physician compensation, lessons from the Medicaid unwinding, disparities in cancer mortality, and privately negotiated hospital fees. 

Health Equity & Access Weekly Roundup: November 9, 2024

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia.

FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Lung Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Idiopathic Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Cholesterol Goals Established for Patients with Diabetes and Metabolic Syndrome

Dyslipidemia of Insulin Resistance Syndrome Explained; Need for Treatment to Reduce Risk Emphasized

Review of Clinical trial Data Reaffirms Safety of Statin Therapy

Protective Effects of HDL-C and Need to Raise Low Levels Explored

Risk Factors Common to Insulin Resistance and Atherosclerosis Explain Why Diabetes is a Cardiovascular Disease

Question and Answer

Heart Protection Study Finds Simvastatin Reduces Vascular Risk in a Wide Range of High-Risk Patients

Lipid-Lowering Therapy Stabilizes Plaque Reduces Events by Limiting Inflammation

New Cholesterol Guidelines Emphasize Risk Assessment